Novel HDL-Targeted Therapies -- The Search Continues

Linda Brookes, MSc


June 12, 2007

In This Article

LY518674: Potent and Selective PPAR-Alpha Agonist

Peroxisome proliferator-activated receptor (PPAR)-alpha agonists have been in development for the treatment of atherosclerosis since they demonstrated promise in animal models of dyslipidemia. It was believed that highly potent and selective PPAR-alpha agonists could improve upon fibrates, such as gemfibrozil and fenofibrate, which also act through modulation of PPAR-alpha, although weakly. However, the first PPAR-alpha agonist to reach phase 2 studies, the compound LY518674, under development with Eli Lilly (Indianapolis, Indiana), has shown mixed results, and it appears unlikely that this class of drugs will be widely developed further.

In 2 phase 2 studies, LY518674 did not show any advantages over fenofibrate in its effects on triglycerides and HDL cholesterol, and it actually raised levels of low-density lipoprotein (LDL) cholesterol and serum creatinine. The results of the 2 studies, both funded by Eli Lilly, were presented at the 2007 ACC meeting by Steven E. Nissen, MD (Cleveland Clinic, Cleveland, Ohio),[1] and published simultaneously in JAMA.[2]

The studies were designed to evaluate the safety and efficacy of LY518674 in one population with atherogenic dyslipidemia, with elevated triglycerides and low levels of HDL cholesterol, and in another population with hypercholesterolemia, with elevated levels of LDL cholesterol.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.